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Protection by exclusion? The (lack of)
inclusion of adults who lack capacity to
consent to research in clinical trials in the
UK
Victoria Shepherd1,2* , Fiona Wood1, Richard Griffith3, Mark Sheehan4 and Kerenza Hood2
Abstract
Background: Around two million adults in the UK have significantly impaired decision-making capacity. However,
there are concerns that this population is under-represented in research, due in part to the challenges around
obtaining consent. Under-representation of populations denies those who would have wanted to participate the
opportunity to make a contribution to society, but also fails to generate results that are applicable to them. Consequently,
the evidence base for their care is poorer than for other populations. We recently published in this journal an analysis of
Participant Information Sheets provided to consultees and legal representatives of adults who lack capacity and noted the
small number of trials designed to include adults who lack capacity. In order to understand how many adults who lack
capacity to consent are actually enrolled in clinical trials, we further explored how many of the participants lacked
capacity, and who acted as a consultee or legal representative on their behalf.
Main text: The ISRCTN registry was searched for UK clinical trials in conditions commonly associated with cognitive
impairment that were designed to include (or not exclude) adults who lack capacity to consent. Details about participants
and capacity status were obtained from published data or directly from the trial teams. Of the 80 retrieved clinical trials
that had completed in the previous 3 years, we identified 15 which included adults who lack capacity to consent. Data
regarding participants’ capacity status were not available for five trials. Where capacity was reported, 5–100% participants
lacked capacity to consent. Trials predominantly utilised personal consultees/legal representatives; however,
39% (634/1631) of participants required a professional to act as consultee/legal representative.
Conclusions: Only a small number of trials including adults who lacked capacity were identified. The majority
of participants were represented by a personal consultee/legal representative; however, between 21 and 100%
of participants across five trials required the involvement of a professional, suggesting it is not uncommon.
Data relating to capacity status were rarely reported, potentially masking the under-representation of adults
who lack capacity. The findings may help researchers and funders target resources towards studies involving
under-represented populations to increase the much-needed evidence base for their care and treatment.
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Background
An estimated two million people in England and Wales
have significantly impaired decision-making through
conditions such as dementia, mental illness, learning dis-
abilities, or other conditions that affect cognitive function
such as delirium or head injury [1]. Adults considered to be
unable to make a particular decision or take a particular ac-
tion for themselves at the time the decision or action needs
to be taken, due to an impairment or disturbance in the
functioning of the mind or brain, are described as lacking
decision-making capacity (Part 1 (2(1, 2) of [2]). This lack
of decision-making capacity may be temporary or perman-
ent, and in England and Wales is determined following an
assessment process laid down in the Mental Capacity Act
2005 [3]. Up to half of patients in acute medical and psychi-
atric healthcare settings lack decision-making capacity
[4, 5], rising to around 70% in settings such as care
homes [6] and approaching 90% in intensive care settings
[7]. These populations often have significant co-morbidities
[8] and experience the greatest and most complex care
needs [9]; therefore, research into conditions that affect
these populations is essential in order to improve their evi-
dence-based care. In many population groups there are sig-
nificant differences between those with and without
capacity. For example, older people living in care homes
who lack capacity are likely to be more frail than those with
capacity and have an increased vulnerability to infection
[6]. However, when it comes to clinical trials, consid-
ered to provide the best quality evidence [10], groups
such as frail older people are often excluded despite
bearing a disproportionate burden of disease and medi-
cation use [11]. We have previously described the result
of having under-researched populations as being evi-
dence biased medicine [12].
There is growing recognition of the importance that
populations included in clinical trials should adequately
represent the population treated in clinical practice [13].
Older people can exhibit unpredictable treatment re-
sponses [14, 15], often experience multiple comorbidities,
and are more likely to experience adverse drug reactions,
yet older people are poorly represented in clinical trials of
drugs they are likely to receive [13, 16]. Similarly, people
with intellectual disabilities have few data available to in-
form their pharmacological care [17]. Pharmacokinetic
studies rarely address alternative delivery routes such as
gastrostomy tubes, and medications are often prescribed
for people with intellectual disabilities, especially psycho-
tropic drugs with significant adverse effects, with minimal
evidence to support their use [17]. This is due in part to
the tendency to exclude adults who lack capacity from
clinical trials [18, 19].
Exclusion from research can result in a lack of evidence-
based care for such populations, who may already experi-
ence significant health disparities [12], resulting in them
living in a ‘knowledge shadow’ [20]. Moreover, the as-
sumption that randomised controlled trials have strong
external validity can be questioned when certain groups
are systematically excluded from those trials [21]. The
under-representation of groups, such as those who lack
decision-making capacity, in clinical trials has been
recognised as a concern by organisations such the UK’s
National Institute for Health Research (NIHR), who are
seeking to identify under-represented groups and de-
velop innovations in clinical trial design and delivery
which could increase recruitment of those groups [22].
Identifying the best approaches to ensure the inclusion
and participation of under-represented or vulnerable
groups in randomised trials has been recognised as a
priority area [23]. Similarly, in the US, the National
Institutes of Health (NIH) are actively seeking ways of
addressing underrepresentation, attempting to shift regu-
lation towards protecting such groups through research,
rather than from research [17]. This approach is reflected
in new ethical guidance which proposes a change to the
position that adults lacking capacity to consent to the
research should only be included if the research is directly
relevant to them, to the position that they must be
included unless there is a scientific justification for their
exclusion [24]. One of the remaining challenges is identify-
ing which groups are under-represented in research.
There is no empirical evidence regarding the amount of
research currently being conducted with populations such
as those who lack capacity to consent [25].
A small number of studies have reviewed the inclusion
and exclusion of specific populations with impaired cap-
acity in clinical trials, such as adults with intellectual dis-
abilities [21], and people with cognitive impairment and
dementia [26]. However, many of the challenges around
including adults who lack capacity are systemic, such as
the complex legal and ethical frameworks [12], or struc-
tural, such as requiring access through gatekeepers [27, 28].
Therefore, understanding the number of trials that are
designed to include participants who lack capacity, and the
proportion of people who lack capacity actually participat-
ing, will provide much needed data about the opportunities
to participate in research that are available to these
populations.
In our study recently published in Trials, in which we
conducted a content analysis of Participant Information
Sheets provided to consultees and legal representatives
of adults who lack capacity, we noted the small number
of trials designed to include participants who lack cap-
acity [29]. What was missing from this account was an
understanding of not just how many trials are designed
to include adults who lack capacity to consent, but how
many participants who lack capacity are subsequently
enrolled in these trials. Knowing how many of the partici-
pants enrolled in trials who lacked capacity to consent will
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aid understanding of the generalisability of the findings to
these populations; help identify under-represented or
underserved groups; and ensure transparency around the
recruitment of under-represented groups. The inadequate
recruitment of traditionally under-represented popula-
tions prevents researchers from creating tailored interven-
tions [30]; therefore, understanding the populations
included in research is an important first step towards
eliminating the existing health disparities that in part arise
from these research inequalities [31]. We explored this
through a further analysis of participant data from trials
completed within the preceding three years, which we
now describe in this commentary.
We also examined the data to determine, for those
participants who lacked capacity to consent, who pro-
vided consent or agreement on the participant’s behalf.
In England and Wales, the legal frameworks govern the
inclusion of adults who lack capacity in clinical trials of
medicinal products under the Medicines for Human Use
(Clinical Trials) Regulations 2004 [32], with other types
of research governed by the Mental Capacity Act 2005
[3]. Under this legal framework, someone who knows
the person who lacks capacity is approached by the
researcher to act as their legal representative or con-
sultee. In circumstances where no-one is available or
willing to act in a personal capacity, then a professional
who cares for the person can act as a professional legal
representative (usually the doctor primarily responsible
for their medical treatment) or nominated consultee on
their behalf [3, 32]. Both personal and professional legal
representatives are required to provide informed consent
on behalf of the adult who lacks capacity based on what
they would have wanted had they the capacity to choose
for themselves, their ‘presumed will’ [32]. A nominated
consultee provides advice regarding trial participation on
the same basis as a personal consultee—what the per-
son’s wishes and feelings would be likely to be about tak-
ing part in the project if he or she had capacity [3]. This
legal basis is regardless of how well the professional legal
representative or nominated consultee knows the person
who lacks capacity to consent, and so in turn the extent
to which they can determine the wishes and feelings of
the person. Our previous study identified particular
issues with the information provided to professionals
acting as a proxy decision-maker (legal representative or
consultee). We were therefore interested in examining
the data reporting on the use of personal versus profes-
sional legal representatives and consultees in order to
consider for the first time the extent of the use of pro-
fessionals as proxy decision-makers in the UK.
Our previous analysis of Participant Information Sheets
and this additional study form part of a larger project
exploring research involving adults who lack capacity to
consent, and the involvement of consultees and legal
representatives. This larger project also included a survey
of health and social care professionals’ knowledge and un-
derstanding about the legal frameworks [33], a qualitative
study exploring families’ experiences of acting as consultee
or legal representative (DECISION Study; in press), and
the development of an intervention to support family
members involved in making decisions about research.
The study reported in this commentary aimed to identify
(1) the number of trials completed in the UK within the
last three years that included adults who lack decision-
making capacity; (2) the number of participants enrolled
in the trials and the percentage who lacked decision-mak-
ing capacity; and (3) who acted as their proxy decision
maker.
Main text
A search of clinical trials was conducted using the
ISRCTN registry [34] to identify trials that included
adults who lacked capacity to consent that were regis-
tered in the UK. We amended the search strategy that
was reported in our Trials paper to identify only trials
that had been completed in the previous three years.
This timeframe was selected in order to reflect current
legal frameworks and guidance and allow time to have
elapsed for analysis of trial data whilst ensuring that in-
vestigators’ contact details were recent enough to enable
effective contact. As in our previous study, eligible studies
were those that (1) included (or did not exclude) adults
who lacked capacity to consent and therefore required
proxy (consultee or legal representative) involvement, and
(2) had recruited participants in the UK. As the focus of the
larger project is on the involvement of consultees and legal
representatives we excluded trials that used a deferred con-
sent model or consent waiver in emergency research set-
tings, such as post cardiac arrest, where obtaining consent
from a legal representative or consulting others is not rea-
sonably practicable [35].
As described in our previous study, trial registries such
as ISRCTN are not necessarily intended for searches of
this nature [29]. However, they are the only available
source for identifying studies across multiple sites,
funders, settings, and conditions or populations under
investigation. This necessitated a pragmatic search strat-
egy which identified condition or population-specific
search terms that would capture trials likely to include
adults who lack capacity to consent. The process for trial
registry searches, eligibility screening of trials, and data
extraction is shown in Fig. 1. The sampling methods
used in the published study and in this analysis are
derived from similar studies assessing the inclusion of
older people [19, 36] and people with intellectual disabil-
ities [21] in medical research.
Searches were conducted in July 2018. Searches were
only limited by relevant fields: trial status (completed
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only), countries of recruitment (United Kingdom), and
either condition (e.g. dementia) or text search (e.g. crit-
ical care). Trial records were then screened for eligibility
by reviewing the participant inclusion and exclusion cri-
teria detailed in the registry record and, where available,
the protocol or other study publication. The published
participant data were extracted from study publications
and reviewed, and the total number of participants, the
number of participants who lacked capacity, and details
of consultee or legal representative involvement were
extracted. Where these data were not available (e.g.
where the number or proportion of participants who
lacked capacity was not stated or the results were un-
published) the data were requested from the research
team, the corresponding authors of study publications,
or the Chief Investigator as applicable. As many data
were unpublished, trial teams or Chief Investigators were
advised when we requested the data that the trials would
not be identifiable in our study. Descriptive statistics
were used to report the number of studies, total number
of participants, and number of participants who lacked
capacity. Where known, the number of participants who
had a personal consultee or legal representative, versus a
nominated consultee or professional legal representative,
were reported.
We identified 81 trials in the conditions or populations
searched for which were completed between 2015 and
2018, of which 15 trials (18%) allowed for the inclusion
of adults who lacked capacity (Table 1).
No data were obtained for three trials as there were no
publications associated with the trial, and there was no
response to our request from the trial team or Chief
Investigator. Of the trials where data were available, the
number of participants recruited ranged from 22–1148
(Table 2). Where data were available, the proportion of
participants who lack capacity ranged from 5 to 100%.
Where data were available relating to the designation
of the consultee or legal representative who was involved
(n = 9), 44.5% (n = 4) of trials involved only personal
consultees/legal representatives, 11% (n = 1) of trials in-
volved only professionals acting as consultee/legal repre-
sentative, and 44.5% (n = 4) had a combination of both
personal and professional consultees/legal representative.
Trials that used a combination were conducted across a
Fig. 1 Trial search and data extraction flow diagram
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range of settings, including long-term care settings such
as care homes (Study ID 07), primary care (Study ID
09), as well as acute critical care settings (Study ID 13).
Where data were provided about participants’ consultee
or legal representative (n = 1631), 39% (n = 634) required
a professional to act on their behalf.
Conclusions
Only a small proportion of clinical trials include adults
who lack capacity to consent, even in populations with
conditions which can be characterised by impaired deci-
sion-making capacity. Of trials designed to specifically
include adults who lacked capacity, for some trials only
around 5% of recruited participants lacked capacity to
consent. Our findings are consistent with previous stud-
ies which surveyed the inclusion of persons with intel-
lectual disabilities in research and found that only 2% of
300 randomly chosen clinical trials published in high im-
pact medical journals clearly included people with intel-
lectual disabilities [21].
Despite the size of the population of people who lack
capacity in England and Wales being roughly equivalent
to the number of people living with cancer in the UK [37],
the number of clinical trials that include participants who
lack capacity appears to be considerably lower than the
number of cancer trials. The number of cancer patients in
the UK participating in clinical studies has risen dramatic-
ally in the past decade from one in 26, to around one in
six patients diagnosed [38]. However, despite initiatives
such as the UK’s Dementia 2020 Challenge which sought
to increase the numbers of people with dementia partici-
pating in research [39], the number of people with condi-
tions associated with impaired decision-making capacity,
such as dementia, remains low [40]. Our findings suggest
Table 1 Number of trials identified and the number designed
to include adults who lack capacity to consent
Trial condition/population Number of clinical
trials completed in
previous 3 years
Number of clinical trials
including adults who
lack capacity to consent
completed in previous
3 years
Parkinson’s disease 12 1
Huntington’s disease 2 0
Dementia 25 6
Intellectual disabilities 1 0
Learning disabilities 4 2
Down’s syndrome 0 0
Stroke 25 2
Traumatic brain injury 0 0
Critical care 8 3
Emergency 4 1
TOTAL 81 15
Table 2 Characteristics of included trials and number of participants
Study ID Trial condition/ population Trial setting Total participants
n (%)
Participants who
lacked capacity
to consent
n (%)
Personal consultee/
legal representative
n (%)
Nominated consultee
or professional legal
representative
n (%)
01 Parkinson’s disease Community 76 4 (5%) 4 (100%) 0
02 Dementia Care homes 34 34 (100%) 34 (100%) 0
03 Dementia Care homes 40 40 (100%) 0 40 (100%)
04 Dementia Community 63 23 (37%) 23 (100%) 0
05 Dementia Hospitals and care homes 14# - - -
06 Dementia Hospitals and care homes 265 - - -
07 Dementia Care homes 987 784 (79%) 336 (43%) 448 (57%)
08 Learning disabilities Community 312 185$(59%) – –
09 Learning disabilities Community 22 18 (82%) 12 (67%) 6 (33%)
10 Stroke Hospitals and community 345 88 (26%) 88 (100%) 0
11 Stroke Hospitals 1148* 540*(47%) 425*(79%) 115*(21%)
12 Critical care Hospitals 120# - - -
13 Critical care Hospitals 103 100 (97%) 75 (75%) 25 (25%)
14 Critical care Hospitals 84 - - -
15 Emergency Hospitals 81# - - -
* Data not verified by investigator
- Data item not available
$ Number of participants with a severe or profound learning disability as trial data reported by type of learning disability and not capacity status
# No trial data available, number of participants is planned sample size as stated in protocol
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that this under-representation is seen in a range of differ-
ent populations experiencing impaired capacity.
The data suggest that professionals acting as a nomi-
nated consultee or professional legal representative for
an adult who lacks capacity to consent is not a rare
occurrence and, in some trials, they alone take on this
role. There may be a number of factors affecting who is
involved in decisions about research participation. It
may be linked to the timeframes within which the par-
ticipant needs to be recruited in an acute setting and the
subsequent availability of a family member within that
timeframe. It was also reported by one trial that family
members of care home residents sometimes felt unable
to make a decision on behalf of their relative, and there-
fore consider the care home staff better placed to do so,
whilst others failed to respond to contact by the research
team. Whilst having legal provisions for professionals to
act as consultee/legal representative is important for
those who would otherwise be unrepresented, there is
currently no advice or guidance available about the role.
There are concerns about whether those acting as nomi-
nated consultees and professional legal representatives
are sufficiently informed and prepared for their role.
Our previous research has shown that there is a lack of
knowledge amongst health and social care professionals
about the legislation governing research involving adults
who lack capacity [33], leading to concerns about the
confidence and competence of care professionals when
including those who lack capacity in their care in med-
ical research. As a result, guidance for professionals is
urgently needed beyond that briefly included in the
Mental Capacity Act Code of Practice [2]. There is also
a need for further research to examine the informational
needs of health and social care professionals acting as
nominated consultees and professional legal representa-
tives and explore how they approach decision-making in
such ethically complex roles.
As reported in our previous study [29] there are a
number of limitations to note. Whilst capacity is consid-
ered to be time and decision-specific rather than global
[3], the circumstances under which a consultee or legal
representative is required, and whether their relationship
with the adult who lacks capacity to consent is a personal
or professional relationship, are relevant factors in this
context. It is recognised that a lack of capacity cannot be
established by reference to a condition [3], and only some
individuals living with these conditions or in these popula-
tions will experience any cognitive impairment, or lack
capacity to consent to a trial. The searches were limited
by the ability to search the registry by condition/subject
area or key words only; for example, it was not possible to
search by capacity status as an inclusion or exclusion cri-
terion, and only conditions considered to be most likely to
include adults with impaired capacity were included in the
search. The sensitivity and specificity of search terms were
highly variable. Terms such as ‘critical care’ and ‘emer-
gency’ appeared relatively precise; however, ‘care home’ as
a text search did not return many trials despite a growing
number of trials in care homes [41], and ‘trauma’ as a con-
dition included psychological trauma. Therefore, a prag-
matic search strategy was used. The searches cannot be
considered to be comprehensive, and eligible trials may
have been conducted that are not included in this study.
Additionally, although there is an expectation that clinical
trials are prospectively registered [42], trials may have
been conducted but not registered. Research studies that
are not defined as clinical trials are not registered and
therefore are not included in this study. Data were not
available on the number of participants who lacked cap-
acity, or who acted as consultee or legal representative, for
a number of the trials.
We have taken the first step towards understanding
the state of play regarding the inclusion of adults who
lack capacity to consent in clinical trials in the UK, and
who acts as a consultee or legal representative on their
behalf. We identified that, firstly, few trials completed in
the UK were designed to include adults who lack deci-
sion-making capacity, which limits the opportunities for
those with cognitive impairments to contribute to
research and may impact on the generalisability of the
results. Secondly, the overall number of participants en-
rolled in the trials who lacked decision-making capacity
was low, which may contribute to the low evidence-base
available for these populations. Lastly, a high proportion
of participants required a professional to act as their
proxy decision maker, which has received little attention
from professional bodies, employing organisations, or those
responsible for research governance and policymaking.
The data presented in our published study and further
described in this commentary are not surprising, but do
provide the first empirical account of the current under-
representation of adults who lack capacity to consent in
clinical trials. However, empirical data on the number of
adults who lack capacity participating in trials remains
low. We encourage investigators to report the proportion
of participants who lack capacity in order to allow a greater
understanding of the representativeness of the trial popula-
tion, and therefore the applicability of trial results, to the
whole clinical population. We have also highlighted the
need for guidance and support for health and social care
professionals acting as nominated consultees and profes-
sional legal representatives. Together with other findings
from our project exploring the involvement of consultees
and legal representatives in research, we hope our results
help researchers, funders, and policy makers target re-
sources towards studies involving under-researched popula-
tions and increase the much-needed evidence base for their
care and treatment.
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